Clorox Stock at 11-Year Low: Is CLX a High-Yield Dividend King Worth Watching in May 2026?
Photo by Jakub Żerdzicki on Unsplash
- Clorox (NYSE: CLX) has fallen 33–38% over the past year to trade near $86–$92 — its lowest level in 11 years — creating a historically rare valuation that contrarian investors are watching closely
- With an annual dividend of $4.96 per share and a yield of roughly 4.9%–5.7% at current prices, CLX ranks among the highest-yielding Dividend Kings in the consumer staples sector
- A Clorox board director purchased 5,000 shares on May 5, 2026, and the 12-month analyst consensus price target sits at approximately $105 — implying roughly 14% upside from recent lows
- The selloff is rooted in an ERP system transition and post-cyberattack recovery costs, not a collapse in brand fundamentals — a distinction that sits at the core of the contrarian investment research case
What Happened
Clorox — the company behind Clorox bleach, Glad trash bags, Burt's Bees, Hidden Valley ranch dressing, and Pine-Sol — has had one of the roughest stretches in its modern history. It began with a major cyberattack in 2023 that knocked out supply chain operations, disrupted product availability across retail shelves, and cost the company hundreds of millions in lost sales and recovery expenses. Just as the business was regaining its footing, Clorox launched a sweeping overhaul of its ERP (enterprise resource planning) system — the integrated software backbone that manages everything from inventory and purchase orders to finance and logistics.
That transition has caused far more disruption than Wall Street anticipated. In Q3 fiscal 2026 (results reported April 30, 2026), Clorox's gross margin — the percentage of revenue left over after direct production costs — declined 140 basis points year-over-year to 43.2%. Management then cut its full-year FY2026 gross margin outlook, guiding for a decline of 250–300 basis points. The company now expects full-year organic sales — revenue growth stripped of acquisitions and currency effects — to fall 5%–9%, with a striking 7.5 percentage points of that drag attributed directly to ERP disruption.
Add rising input costs and inflation-fatigued consumers trading down to private-label store brands, and you have a stock that has shed 33–38% in the past 12 months, landing near $86–$92 — an 11-year low. For those doing their own investment research, one question rises above the rest: is this a business in structural decline, or a well-established brand caught in a temporary operational storm?
Photo by Venti Views on Unsplash
What the Data Tells Us
Answering that question requires separating the operational noise from the underlying business fundamentals. Think of it like a highly rated restaurant that had a kitchen fire — the dining room reputation (the brand) is still standing; it is the back-of-house systems that are temporarily in chaos. That framing sets the stage for what the numbers actually show.
Start with the dividend track record. Clorox has raised its dividend for 50 consecutive years, earning the rare title of "Dividend King" — a distinction held by fewer than 60 U.S. companies in history. The current annual dividend of $4.96 per share translates to a yield of roughly 4.9%–5.7% at recent prices, among the highest in the consumer staples sector and nearly four times the S&P 500 average. Wall Street forecasts FY2026 EPS (earnings per share — the company's profit divided by its total share count) of approximately $5.98, with a range of $5.54–$6.46 across 21 analysts. At that earnings outlook, the dividend appears covered, though the payout ratio (the fraction of earnings paid out as dividends) of roughly 83% leaves limited margin for error.
The valuation picture is where the contrarian stock analysis gets genuinely compelling. According to AInvest analysts, CLX currently trades at roughly a 63% P/E discount — P/E ratio meaning the stock price divided by earnings per share — relative to its own historical norms. In plain terms: investors are paying less for every dollar of Clorox's earnings today than at almost any point in more than a decade. At a forward P/E of roughly 14–16x, that is modest for a branded consumer goods company with a 50-year dividend growth streak intact.
Market trends in the broader sector reinforce the contrarian thesis. Consumer staples have underperformed the S&P 500 throughout 2025–2026, as investors rotated toward growth and AI-adjacent names. Historically, that kind of rotation eventually reverses, and defensive dividend stocks often re-rate sharply when it does. Clorox also priced a $1.5 billion debt offering in three parts in early 2026, raising capital to fund the ERP transition and general corporate purposes — a move that adds near-term leverage but confirms full access to capital markets, which matters when evaluating the durability of the dividend.
The insider activity adds a meaningful signal. A Clorox board director purchased 5,000 shares on May 5, 2026 — a notable move, given that insiders buy for essentially one reason: they expect the price to rise. The 12-month analyst consensus price target of approximately $105 implies about 14% upside from current lows; the consensus Hold rating across 12 analysts reflects near-term caution about execution risk, not a bearish view on the underlying business. As The Motley Fool put it in summarizing the contrarian case: "Given the weak expectations and Clorox's stock price hovering around an 11-year low, investors should focus on Clorox's direction over the next few years rather than its upcoming quarterly results." FY2025 revenue came in at $7.10 billion (up 0.16% year-over-year), while FY2025 earnings of $810 million represented a 189% year-over-year recovery as operations normalized after the cyberattack — a powerful reminder that Clorox has demonstrated an ability to bounce back from major operational shocks.
Key Companies and Supply Chain
Placing Clorox in competitive context is essential to any serious sector analysis. The consumer staples supply chain runs from raw material inputs — surfactants, resins, agricultural commodities — through manufacturing and distribution, with each layer exposed to cost pressures and logistics disruptions that affect pricing power and margins.
Clorox (NYSE: CLX) — The focal company. Its diversified portfolio across cleaning, personal care (Burt's Bees), food (Hidden Valley), and trash bags (Glad) provides meaningful category breadth, but the ERP migration has temporarily impaired operational execution across all segments. Investors are watching the Q4 FY2026 earnings call (expected July 2026) as the next major checkpoint for signs of stabilization.
Procter & Gamble (NYSE: PG) — The sector's dominant player, with a market cap exceeding $350 billion and its own Dividend King credentials. P&G has faced the same input cost headwinds and private-label competition as Clorox, but its more globally diversified operations and scale have provided greater resilience. Standard practice in stock analysis is to benchmark CLX against PG on gross margin trajectory, dividend coverage ratio, and revenue growth to assess whether CLX's valuation discount is justified or excessive.
Church & Dwight (NYSE: CHD) — Maker of Arm & Hammer and OxiClean, a direct peer in cleaning and personal care. CHD has navigated its own operational transitions more smoothly in recent years, reflected in its relative outperformance. It serves as a useful comparator for understanding how execution risk is priced in the sector over time.
Spectrum Brands (NYSE: SPB) — Another consumer products company that has experienced ERP-related disruptions in recent years, offering a reference case for how markets eventually reprice execution risk once transitions stabilize.
Private-label competition from Walmart (NYSE: WMT) and Costco (NASDAQ: COST) remains a structural headwind across the category. However, brand loyalty in cleaning and hygiene — the heart of Clorox's business — historically reasserts itself as economic conditions ease, a central assumption in the long-term bull case for CLX.
What Should You Do? 3 Action Steps
The 7.5 percentage point organic sales drag tied to the ERP migration is the single most consequential variable in any near-term view of CLX. It is worth researching what management has communicated about specific go-live phases, which business segments are most disrupted, and what leading indicators signal improvement. The Q4 FY2026 earnings call (expected July 2026) is the most important near-term checkpoint. Listen for language around "full go-live," supply chain order accuracy, and whether the 5%–9% organic sales decline guidance narrows or widens.
Investors are watching how Clorox stacks up against peers on gross margin trajectory, interest coverage ratio (how many times operating earnings cover annual interest payments), and leverage levels before drawing conclusions. CLX's $1.5 billion debt offering in early 2026 deserves close examination alongside Procter & Gamble's and Church & Dwight's capital structures. This comparative stock analysis can reveal whether CLX's 63% P/E discount to its own historical norms represents a genuine opportunity or a justified markdown for elevated financial risk.
Rotations back into defensive sectors can happen faster than most investors expect — and when they do, high-yield dividend names like CLX tend to move sharply. Because near-term earnings remain under pressure and the ERP transition introduces genuine execution uncertainty, a phased, gradual approach to building exposure — rather than committing a full position at once — is worth researching as a risk management framework. The board director's 5,000-share purchase on May 5, 2026 is an encouraging data point to track alongside quarterly earnings progress, not a standalone signal to act on.
Frequently Asked Questions
Is Clorox CLX stock a good investment during its ERP transition in 2026?
This is educational analysis, not financial advice — but here is what the data shows. AInvest analysts describe CLX as a "Wide-Moat Dividend Giant Trapped in ERP Transition," arguing the selloff is execution-driven rather than a reflection of permanent brand damage. With a 63% P/E discount to historical norms and 50 consecutive years of dividend increases, the setup is historically unusual. The Motley Fool's contrarian view specifically notes that patient investors with a 3-to-5-year horizon may find Clorox's direction over that period more important than its next quarterly result. Near-term risk remains elevated until the ERP transition stabilizes and gross margin begins recovering from the guided 250–300 basis point decline.
Why is Clorox stock falling to an 11-year low in May 2026?
CLX's decline to approximately $86–$92 — its lowest level in 11 years — reflects a convergence of headwinds rather than any single cause. A 2023 cyberattack disrupted supply chain operations and cost the company hundreds of millions in lost revenue. An ongoing ERP system overhaul is creating a 7.5 percentage point drag on organic sales and a gross margin decline to 43.2% in Q3 FY2026. Rising input costs and inflation-fatigued consumers choosing private-label alternatives have further pressured results. Market trends also played a role: consumer staples broadly underperformed the S&P 500 in 2025–2026 as investors favored growth and AI-adjacent stocks, amplifying the selloff.
How safe is Clorox's dividend given that earnings are under pressure in 2026?
Clorox has raised its dividend for 50 straight years — a streak that defines Dividend King status — and the current $4.96 annual dividend appears covered by the Wall Street EPS consensus of approximately $5.98 for FY2026. That implies a payout ratio of roughly 83%, which is elevated but not uncommon for a consumer staples company in a temporary earnings trough. The primary risk is further gross margin deterioration beyond the guided 250–300 basis point decline for FY2026: if earnings fall significantly below the $5.54–$6.46 analyst forecast range, dividend coverage becomes tighter. Clorox's access to capital markets — evidenced by the $1.5 billion debt offering in early 2026 — provides a secondary buffer.
What is the analyst price target for Clorox CLX stock heading into the second half of 2026?
The 12-month analyst consensus price target for CLX is approximately $105, implying roughly 14% upside from the recent $86–$92 trading range. This target reflects input from 12 analysts whose consensus rating is Hold — signaling near-term caution about execution risk rather than a bearish fundamental stance. Wall Street's FY2026 EPS forecast spans $5.54 to $6.46 across 21 analysts, with a midpoint near $5.98. The most notable recent insider data point in any stock analysis of CLX is the board director's purchase of 5,000 shares on May 5, 2026, which suggests at least one person with close visibility to company operations sees current prices as attractive.
Are consumer staples dividend stocks worth researching as a buy when inflation is moderating in 2026?
Sector analysis of historical market trends shows consumer staples tend to re-rate meaningfully when growth fears intensify or when investor sentiment rotates back toward defensive, income-producing assets. With inflation moderating and Clorox's brand portfolio — Clorox, Glad, Burt's Bees, Hidden Valley, and Pine-Sol — retaining strong household penetration, data suggests the long-term setup may be worth researching for income-focused investors with patience. That said, timing sector rotations is notoriously difficult. Most investment research frameworks recommend evaluating entry points based on valuation and dividend sustainability rather than attempting to predict macro turning points — and on both of those metrics, CLX currently sits at historically unusual levels.
Disclaimer: This article is for educational and informational purposes only. It does not constitute financial advice, a recommendation, or an endorsement of any security. Always do your own research and consult a licensed financial advisor before making investment decisions.
No comments:
Post a Comment